Kim Brøsen

Kim Brøsen

Auto-generated profile, based on publicly available information

Kim Brøsen

Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1990 in Pain
Verified
Journal Article
Closed access
SSSøren H. Sindrup
Søren H. Sindrup
LGLars F. Gram
Lars F. Gram
KBKim Brøsen
Kim Brøsen
OEOle Eshøj
Ole Eshøj
EMErik F. Mogensen
Erik F. Mogensen
The effect of the selective serotonin reuptake inhibitor paroxetine on diabetic neuropathy symptoms was examined in comparison to imipramine and placebo in a randomised, double-blind, cross-over study. Paroxetine was given as a fixed dose of 40 mg/day, while the dose of imipramine was adjusted to yield optimal plasma levels of imipramine plus desipramine of 400-600 nM. Paroxetine significantly reduced the symptoms of neuropathy as measured by both observer- and self-rating, but was somewhat less effective than imipramine. However, patients showing a weaker response to paroxetine than to imipramine had lower plasma concentrations of paroxetine than patients with similar response to the 2 drugs. On imipramine 5 patients dropped out because of intolerable side effects and 4 of 19 patients completing the study reported withdrawal symptoms after discontinuing imipramine. On paroxetine no patients dropped out due to side effects and no withdrawal symptoms were reported. Self-rating showed no depressive symptoms at baseline, and no changes during the study. Neither paroxetine nor imipramine caused changes in objective measures of peripheral nerve function. In conclusion, 40 mg paroxetine/day significantly reduced the symptoms in peripheral diabetic neuropathy, and it was suggested that by dose adjustment on the basis of drug level monitoring, paroxetine may become as effective as imipramine. Paroxetine was devoid of the often disturbing autonomic side effects limiting the use of imipramine in several patients.

1 September 2001 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
JKJ. Kirchheiner
J. Kirchheiner
KBK. Brøsen
K. Brøsen
MDM. L. Dahl
M. L. Dahl
LGL. F. Gram
L. F. Gram
SKSiegfried Kasper
Siegfried Kasper
JBJ. Brockmöller
J. Brockmöller

1 December 1996 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
LPLars Poulsen
Lars Poulsen
LALars Arendt-Nielsen
Lars Arendt-Nielsen
KBKim Brøsen
Kim Brøsen
SSSøren H. Sindrup
Søren H. Sindrup

4 August 1990 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
JHJ. Hallas
J. Hallas
BHB. Harvald
B. Harvald
LGL. F. Gram
L. F. Gram
EGE. Grodum
E. Grodum
KBK. Brøsen
K. Brøsen
NDN. Damsbo
N. Damsbo

1 March 1993 in Biochemical Pharmacology
Verified
Journal Article
Closed access
KBKim Brøsen
Kim Brøsen
ESErik Skjelbo
Erik Skjelbo
BRBirgitte B. Rasmussen
Birgitte B. Rasmussen
HPHenrik Enghusen Poulsen
Henrik Enghusen Poulsen
Steffen LoftSteffen Loft
Steffen Loft

1 October 1999 in Pain
Verified
Journal Article
Closed access
SSSøren H Sindrup
Søren H Sindrup
GAGrethe Andersen
Grethe Andersen
CMClaus Madsen
Claus Madsen
TSTorben Smith
Torben Smith
KBKim Brøsen
Kim Brøsen
TJTroels S Jensen
Troels S Jensen
It is generally believed that opioids relieve neuropathic pain less effectively than nociceptive pain and that they have no effect on some of the key characteristics of neuropathic pain such as touch-evoked pain (allodynia). Tramadol is an analgesic drug acting directly on opioid receptors and indirectly on monoaminergic receptor systems. The aim of this trial was to determine whether tramadol relieved painful polyneuropathy and reduced allodynia. The study design was randomised, double-blind, placebo-controlled and cross-over. After baseline observations, 45 patients were assigned to one of the two treatment sequences. The dose of tramadol slow-release tablets was titrated to at least 200 mg/day and at highest 400 mg/day. During the two treatment periods of 4 weeks duration, patients rated pain, paraesthesia and touch-evoked pain by use of 0-10 point numeric rating scales. Mechanical allodynia induced by stimulation with an electronic toothbrush was rated at the end of each treatment period with a similar scale. Thirty-four patients completed the study. Their ratings for pain (median 4 vs. 6, P=0.001), paraesthesia (4 vs. 6, P=0.001) and touch-evoked pain (3 vs. 5, P/=50% pain relief was 4.3 (95% confidence interval 2.4-20). It is concluded that tramadol appears to relieve both ongoing pain symptoms and the key neuropathic pain feature allodynia in polyneuropathy.